These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 23444283)
21. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil. Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848 [TBL] [Abstract][Full Text] [Related]
23. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Johnston A; He X; Holt DW Transplantation; 2006 Dec; 82(11):1413-8. PubMed ID: 17164710 [TBL] [Abstract][Full Text] [Related]
24. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus. Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641 [TBL] [Abstract][Full Text] [Related]
26. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172 [TBL] [Abstract][Full Text] [Related]
27. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis. Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293 [TBL] [Abstract][Full Text] [Related]
28. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients. Sollinger H Transplant Proc; 2004 Mar; 36(2 Suppl):517S-520S. PubMed ID: 15041399 [TBL] [Abstract][Full Text] [Related]
37. The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. Shah T; Tellez-Corrales E; Yang JW; Qazi Y; Wang J; Wilson J; Hutchinson I; Min DI Ther Drug Monit; 2011 Feb; 33(1):45-9. PubMed ID: 21099740 [TBL] [Abstract][Full Text] [Related]
38. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518 [TBL] [Abstract][Full Text] [Related]
39. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. Abd Rahman AN; Tett SE; Staatz CE Clin Pharmacokinet; 2013 May; 52(5):303-31. PubMed ID: 23475567 [TBL] [Abstract][Full Text] [Related]
40. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Budde K; Knoll G; Curtis J; Chan L; Pohanka E; Gentil M; Seifu Y; Marrast AC; Neumayer HH; Clin Nephrol; 2006 Aug; 66(2):103-11. PubMed ID: 16939066 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]